Emsella Chair Therapy for Overactive Bladder
(EmsellaOAB Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing the Emsella Chair, which uses electromagnetic waves to strengthen pelvic muscles, on patients with overactive bladder. These patients often seek non-surgical treatments due to medication side effects. The chair helps by making the pelvic muscles stronger, similar to doing many Kegel exercises.
Will I have to stop taking my current medications?
If you are on a stable dose of antimuscarinics or beta-3 agonists, you can continue taking them during the study. If you have stopped these medications, you must have done so at least 2 weeks before joining the trial. You should not start any new treatments for overactive bladder during the study.
How does Emsella Chair Therapy differ from other treatments for overactive bladder?
What data supports the effectiveness of the Emsella Chair treatment for overactive bladder?
The research highlights that alternative treatments like sacral neuromodulation, which involves stimulating nerves to improve bladder control, have shown significant improvement in bladder function and quality of life for patients with overactive bladder. This suggests that treatments like the Emsella Chair, which also use electromagnetic stimulation, may offer similar benefits.678910
Who Is on the Research Team?
Kenneth M Peters, MD
Principal Investigator
Corewell Health William Beaumont University Hospital
Are You a Good Fit for This Trial?
This trial is for adults over 18 with overactive bladder symptoms lasting at least 3 months, who've tried and failed conservative treatments. They must be on stable medication or have stopped such medications for two weeks, able to use the toilet without help, not start new OAB treatments during the study, and if female of child-bearing age, agree to use birth control.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Emsella Chair or Sham treatment twice a week for 4 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Durability Assessment
Assessment of treatment durability and safety 4 weeks after primary endpoint
What Are the Treatments Tested in This Trial?
Interventions
- BTL Emsella Chair
- Sham BTL Emsella Chair
BTL Emsella Chair is already approved in United States for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
William Beaumont Hospitals
Lead Sponsor